Free tool
FAERS Monitor: Kengreal
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 204958 or its brand name (Kengreal, Cangrelor). Reports on generic versions are filed under their own applications.
Reports
404
Serious
290
72% of reports
Hospitalization
83
Death reported
84
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use160
- vascular stent thrombosis32
- drug ineffective31
- haemorrhage26
- death22
- no adverse event20
- cardiac arrest18
- inappropriate schedule of product administration18
- cardiogenic shock15
- gastrointestinal haemorrhage14
- dyspnoea12
- labelled drug-drug interaction medication error12
- cerebral haemorrhage11
- intentional product use issue11
- haemorrhage intracranial10
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 8 |
| 2014 | 2 |
| 2015 | 7 |
| 2016 | 19 |
| 2017 | 29 |
| 2018 | 22 |
| 2019 | 46 |
| 2020 | 55 |
| 2021 | 18 |
| 2022 | 28 |
| 2023 | 40 |
| 2024 | 53 |
| 2025 | 48 |
| 2026 | 22 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,755 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| vascular stent thrombosisSignal | 32 | 831.7 | 594.8 | 25,326 |
| labelled drug-drug interaction medication errorSignal | 12 | 70.8 | 40.5 | 756 |
| cardiogenic shockSignal | 15 | 54.5 | 33.1 | 735 |
| haemorrhage intracranialSignal | 10 | 34.8 | 18.9 | 296 |
| cerebral haemorrhageSignal | 11 | 16.0 | 8.9 | 140 |
| haemorrhageSignal | 26 | 13.0 | 8.9 | 276 |
| cardiac arrestSignal | 18 | 11.4 | 7.2 | 160 |
| off label useSignal | 160 | 9.5 | 8.4 | 1,263 |
| gastrointestinal haemorrhageSignal | 14 | 8.7 | 5.2 | 88 |
| intentional product use issueSignal | 11 | 6.5 | 3.6 | 46 |
| no adverse eventSignal | 20 | 5.7 | 3.7 | 74 |
| inappropriate schedule of product administrationSignal | 18 | 5.2 | 3.3 | 57 |
| death | 22 | 1.3 | 0.9 | 2 |
| drug ineffective | 31 | 1.2 | 0.9 | 1 |
| dyspnoea | 12 | 1.1 | 0.6 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.